Beyond the biomarker role: prostate-specific antigen (PSA) in the prostate cancer microenvironment

1.

Yousef, G. M., Kopolovic, A. D., Elliott, M. B., & Diamandis, E. P. (2003). Genomic overview of serine proteases. Biochemical and Biophysical Research Communications, 305(1), 28–36. https://doi.org/10.1016/s0006-291x(03)00638-7.CrossRefPubMed

2.

Lundwall, A., Band, V., Blaber, M., Clements, J. A., Courty, Y., Diamandis, E. P., et al. (2006). A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biological Chemistry, 387(6), 637–641. https://doi.org/10.1515/BC.2006.082.CrossRefPubMed

3.

Clements, J. A., Willemsen, N. M., Myers, S. A., & Dong, Y. (2004). The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. Critical Reviews in Clinical Laboratory Sciences, 41(3), 265–312. https://doi.org/10.1080/10408360490471931.CrossRefPubMed

4.

Lundwall, A., & Lilja, H. (1987). Molecular cloning of human prostate specific antigen cDNA. FEBS Letters, 214(2), 317–322. https://doi.org/10.1016/0014-5793(87)80078-9.CrossRefPubMed

5.

Paju, A., Bjartell, A., Zhang, W. M., Nordling, S., Borgstrom, A., Hansson, J., et al. (2000). Expression and characterization of trypsinogen produced in the human male genital tract. The American Journal of Pathology, 157(6), 2011–2021. https://doi.org/10.1016/S0002-9440(10)64840-7.CrossRefPubMedPubMedCentral

6.

Carvalho, A. L., Sanz, L., Barettino, D., Romero, A., Calvete, J. J., & Romao, M. J. (2002). Crystal structure of a prostate kallikrein isolated from stallion seminal plasma: a homologue of human PSA. Journal of Molecular Biology, 322(2), 325–337.CrossRefPubMed

7.

Skala, W., Utzschneider, D. T., Magdolen, V., Debela, M., Guo, S., Craik, C. S., et al. (2014). Structure-function analyses of human kallikrein-related peptidase 2 establish the 99-loop as master regulator of activity. The Journal of Biological Chemistry, 289(49), 34267–34283. https://doi.org/10.1074/jbc.M114.598201.CrossRefPubMedPubMedCentral

8.

Denmeade, S. R., Sokoll, L. J., Chan, D. W., Khan, S. R., & Isaacs, J. T. (2001). Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models. Prostate, 48(1), 1–6. https://doi.org/10.1002/pros.1075.CrossRefPubMed

9.

Lilja, H. (1985). A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. The Journal of Clinical Investigation, 76(5), 1899–1903. https://doi.org/10.1172/JCI112185.CrossRefPubMedPubMedCentral

10.

Lilja, H., & Laurell, C. B. (1985). The predominant protein in human seminal coagulate. Scandinavian Journal of Clinical and Laboratory Investigation, 45(7), 635–641.CrossRefPubMed

11.

Stenman, U. H., Leinonen, J., Zhang, W. M., Finne, P., & Wu, P. (1998). The clinical importance of free prostate-specific antigen (PSA). Current Opinion in Urology, 8(5), 393–399.CrossRefPubMed

12.

Lilja, H., Ulmert, D., & Vickers, A. J. (2008). Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nature Reviews. Cancer, 8(4), 268–278. https://doi.org/10.1038/nrc2351.CrossRefPubMed

13.

Zhu, L., Leinonen, J., Zhang, W. M., Finne, P., & Stenman, U. H. (2003). Dual-label immunoassay for simultaneous measurement of prostate-specific antigen (PSA)-alpha1-antichymotrypsin complex together with free or total PSA. Clinical Chemistry, 49(1), 97–103.CrossRefPubMed

14.

Stenman, U. H., Leinonen, J., Alfthan, H., Rannikko, S., Tuhkanen, K., & Alfthan, O. (1991). A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Research, 51(1), 222–226.PubMed

15.

Ito, K., Yamamoto, T., Ohi, M., Kurokawa, K., Suzuki, K., & Yamanaka, H. (2003). Free/total PSA ratio is a powerful predictor of future prostate cancer morbidity in men with initial PSA levels of 4.1 to 10.0 ng/ml. Urology, 61(4), 760–764. https://doi.org/10.1016/S0090-4295(02)02427-5.CrossRefPubMed

16.

Bangma, C. H., Wildhagen, M. F., Yurdakul, G., Schroder, F. H., & Blijenberg, B. G. (2004). The value of (-7, -5) pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer. BJU International, 93(6), 720–724. https://doi.org/10.1111/j.1464-410X.2003.04733.x.CrossRefPubMed

17.

Mikolajczyk, S. D., Catalona, W. J., Evans, C. L., Linton, H. J., Millar, L. S., Marker, K. M., et al. (2004). Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clinical Chemistry, 50(6), 1017–1025. https://doi.org/10.1373/clinchem.2003.026823.CrossRefPubMed

18.

Kornberg, Z., Cooperberg, M. R., Spratt, D. E., & Feng, F. Y. (2018). Genomic biomarkers in prostate cancer. Translational Andrology and Urology, 7(3), 459–471. https://doi.org/10.21037/tau.2018.06.02.CrossRefPubMedPubMedCentral

19.

Morgan, T., Palapattu, G., & Wei, J. (2015). Screening for prostate cancer-beyond total PSA, utilization of novel biomarkers. Current Urology Reports, 16(9), 63. https://doi.org/10.1007/s11934-015-0537-3.CrossRefPubMed

20.

Saini, S. (2016). PSA and beyond: alternative prostate cancer biomarkers. Cellular Oncology (Dordrecht), 39(2), 97–106. https://doi.org/10.1007/s13402-016-0268-6.CrossRef

21.

Punnen, S., Pavan, N., & Parekh, D. J. (2015). Finding the wolf in sheep’s clothing: the 4K score is a novel blood test that can accurately identify the risk of aggressive prostate cancer. Revista de Urología, 17(1), 3–13.

22.

Whitbread, A. K., Veveris-Lowe, T. L., Dong, Y., Tan, O. L., Gardiner, R., Samaratunga, H. M., et al. (2010). Expression of PSA-RP2, an alternatively spliced variant from the PSA gene, is increased in prostate cancer tissues but the protein is not secreted from prostate cancer cells. Biological Chemistry, 391(4), 461–466. https://doi.org/10.1515/BC.2010.043.CrossRefPubMed

23.

Farashi, S., Kryza, T., Clements, J., & Batra, J. (2019). Post-GWAS in prostate cancer: from genetic association to biological contribution. Nature Reviews. Cancer, 19(1), 46–59. https://doi.org/10.1038/s41568-018-0087-3.CrossRefPubMed

24.

Srinivasan, S., Stephens, C., Wilson, E., Panchadsaram, J., DeVoss, K., Koistinen, H., et al. (2019). Prostate cancer risk-associated single-nucleotide polymorphism affects prostate-specific antigen glycosylation and its function. Clinical Chemistry, 65(1), e1–e9. https://doi.org/10.1373/clinchem.2018.295790.CrossRefPubMed

25.

Tkac, J., Gajdosova, V., Hroncekova, S., Bertok, T., Hires, M., Jane, E., et al. (2019). Prostate-specific antigen glycoprofiling as diagnostic and prognostic biomarker of prostate cancer. Interface Focus, 9(2), 20180077. https://doi.org/10.1098/rsfs.2018.0077.CrossRefPubMedPubMedCentral

26.

Schroder, F. H., Roobol, M. J., van der Kwast, T. H., Kranse, R., & Bangma, C. H. (2006). Does PSA velocity predict prostate cancer in pre-screened populations? European Urology, 49(3), 460–465; discussion 465. https://doi.org/10.1016/j.eururo.2005.12.026.CrossRefPubMed

27.

Vickers, A. J., Wolters, T., Savage, C. J., Cronin, A. M., O'Brien, M. F., Pettersson, K., et al. (2009). Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. European Urology, 56(5), 753–760. https://doi.org/10.1016/j.eururo.2009.07.047.CrossRefPubMedPubMedCentral

28.

Loeb, S., Roehl, K. A., Nadler, R. B., Yu, X., & Catalona, W. J. (2007). Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml. The Journal of Urology, 178(6), 2348–2352; discussion 2352-2343. https://doi.org/10.1016/j.juro.2007.08.016.CrossRefPubMed

29.

Freedland, S. J. (2005). Can we preoperatively identify men who are at high risk for aggressive prostate cancer? Nature Clinical Practice. Urology, 2(12), 584–585. https://doi.org/10.1038/ncpuro0355.CrossRefPubMed

30.

Gronberg, H., Adolfsson, J., Aly, M., Nordstrom, T., Wiklund, P., Brandberg, Y., et al. (2015). Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study. The Lancet Oncology, 16(16), 1667–1676. https://doi.org/10.1016/S1470-2045(15)00361-7.CrossRefPubMed

31.

Sooriakumaran, P. (2011). Smarter screening for prostate cancer: for the few, not the many? A stratified approach based on baseline risk. Expert Review of Anticancer Therapy, 11(2), 169–172. https://doi.org/10.1586/era.10.233.CrossRefPubMed

32.

Tan, G. H., Nason, G., Ajib, K., Woon, D. T. S., Herrera-Caceres, J., Alhunaidi, O., et al. (2019). Smarter screening for prostate cancer. World Journal of Urology, 37(6), 991–999. https://doi.org/10.1007/s00345-019-02719-5.CrossRefPubMed

33.

Rehault, S., Monget, P., Mazerbourg, S., Tremblay, R., Gutman, N., Gauthier, F., et al. (2001). Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3. European Journal of Biochemistry, 268(10), 2960–2968. https://doi.org/10.1046/j.1432-1327.2001.02185.x.CrossRefPubMed

34.

Bindukumar, B., Schwartz, S. A., Nair, M. P., Aalinkeel, R., Kawinski, E., & Chadha, K. C. (2005). Prostate-specific antigen modulates the expression of genes involved in prostate tumor growth. Neoplasia, 7(5), 544.PubMedPubMedCentral

35.

Niu, Y., Yeh, S., Miyamoto, H., Li, G., Altuwaijri, S., Yuan, J., et al. (2008). Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation. Cancer Research, 68(17), 7110–7119. https://doi.org/10.1158/0008-5472.CAN-07-6507.CrossRefPubMedPubMedCentral

36.

Humphrey, P. A. (2007). Diagnosis of adenocarcinoma in prostate needle biopsy tissue. Journal of Clinical Pathology, 60(1), 35–42. https://doi.org/10.1136/jcp.2005.036442.CrossRefPubMedPubMedCentral

37.

Li, J., & Wang, Z. (2016). The pathology of unusual subtypes of prostate cancer. Chinese Journal of Cancer Research, 28(1), 130–143. https://doi.org/10.3978/j.issn.1000-9604.2016.01.06.CrossRefPubMedPubMedCentral

38.

Datta, K., Muders, M., Zhang, H., & Tindall, D. J. (2010). Mechanism of lymph node metastasis in prostate cancer. Future Oncology, 6(5), 823–836. https://doi.org/10.2217/fon.10.33.CrossRefPubMed

39.

Chen, C., He, H., Yu, Z., Qiu, Y., & Wang, X. (2016). Renal and retroperitoneal metastasis from prostate adenocarcinoma: a case report. World Journal of Surgical Oncology, 14, 74. https://doi.org/10.1186/s12957-016-0834-4.CrossRefPubMedPubMedCentral

40.

Sepulveda, L., Gorgal, T., Pires, V., & Rodrigues, F. (2015). Prostate cancer metastatic to the cervical lymph nodes. Case Reports in Urology, 2015, 263978. https://doi.org/10.1155/2015/263978.CrossRefPubMedPubMedCentral

41.

Messiou, C., Cook, G., & deSouza, N. M. (2009). Imaging metastatic bone disease from carcinoma of the prostate. British Journal of Cancer, 101(8), 1225–1232. https://doi.org/10.1038/sj.bjc.6605334.CrossRefPubMedPubMedCentral

42.

Batson, O. V. (1940). The function of the vertebral veins and their role in the spread of metastases. Annals of Surgery, 112(1), 138–149. https://doi.org/10.1097/00000658-194007000-00016.CrossRefPubMedPubMedCentral

43.

Markowska, A. I., Liu, F. T., & Panjwani, N. (2010). Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response. The Journal of Experimental Medicine, 207(9), 1981–1993. https://doi.org/10.1084/jem.20090121.CrossRefPubMedPubMedCentral

44.

Williams, S. A., Jelinek, C. A., Litvinov, I., Cotter, R. J., Isaacs, J. T., & Denmeade, S. R. (2011). Enzymatically active prostate-specific antigen promotes growth of human prostate cancers. Prostate, 71(15), 1595–1607. https://doi.org/10.1002/pros.21375.CrossRefPubMedPubMedCentral

45.

Nabatchian, F., Moradi, A., Aghaei, M., Ghanadian, M., Jafari, S. M., & Tabesh, S. (2017). New 6(17)-epoxylathyrane diterpene: aellinane from Euphorbia aellenii induces apoptosis via mitochondrial pathway in ovarian cancer cell line. Toxicology Mechanisms and Methods, 27(8), 622–630. https://doi.org/10.1080/15376516.2017.1347735.CrossRefPubMed

46.

Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646–674. https://doi.org/10.1016/j.cell.2011.02.013.CrossRefPubMed

47.

Filippou, P. S., Karagiannis, G. S., Musrap, N., & Diamandis, E. P. (2016). Kallikrein-related peptidases (KLKs) and the hallmarks of cancer. Critical Reviews in Clinical Laboratory Sciences, 53(4), 277–291. https://doi.org/10.3109/10408363.2016.1154643.CrossRefPubMed

48.

Bindukumar, B., Schwartz, S. A., Nair, M. P., Aalinkeel, R., Kawinski, E., & Chadha, K. C. (2005). Prostate-specific antigen modulates the expression of genes involved in prostate tumor growth. Neoplasia, 7(3), 241–252. https://doi.org/10.1593/neo.04529.CrossRefPubMedPubMedCentral

49.

Saraswati, S., Block, A. S., Davidson, M. K., Rank, R. G., Mahadevan, M., & Diekman, A. B. (2011). Galectin-3 is a substrate for prostate specific antigen (PSA) in human seminal plasma. Prostate, 71(2), 197–208. https://doi.org/10.1002/pros.21236.CrossRefPubMedPubMedCentral

50.

Wang, Y., Nangia-Makker, P., Tait, L., Balan, V., Hogan, V., Pienta, K. J., et al. (2009). Regulation of prostate cancer progression by galectin-3. The American Journal of Pathology, 174(4), 1515–1523. https://doi.org/10.2353/ajpath.2009.080816.CrossRefPubMedPubMedCentral

51.

Emami, N., & Diamandis, E. P. (2007). New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family. Molecular Oncology, 1(3), 269–287. https://doi.org/10.1016/j.molonc.2007.09.003.CrossRefPubMedPubMedCentral

52.

Pezzato, E., Sartor, L., Dell'Aica, I., Dittadi, R., Gion, M., Belluco, C., et al. (2004). Prostate carcinoma and green tea: PSA-triggered basement membrane degradation and MMP-2 activation are inhibited by (-)epigallocatechin-3-gallate. International Journal of Cancer, 112(5), 787–792. https://doi.org/10.1002/ijc.20460.CrossRefPubMed

53.

Webber, M. M., Waghray, A., & Bello, D. (1995). Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clinical Cancer Research, 1(10), 1089–1094.PubMed

54.

Lilja, H., Oldbring, J., Rannevik, G., & Laurell, C. B. (1987). Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. The Journal of Clinical Investigation, 80(2), 281–285. https://doi.org/10.1172/JCI113070.CrossRefPubMedPubMedCentral

55.

Lawrence, M. G., Lai, J., & Clements, J. A. (2010). Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus. Endocrine Reviews, 31(4), 407–446. https://doi.org/10.1210/er.2009-0034.CrossRefPubMed

56.

Veveris-Lowe, T. L., Lawrence, M. G., Collard, R. L., Bui, L., Herington, A. C., Nicol, D. L., et al. (2005). Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Endocrine-Related Cancer, 12(3), 631–643. https://doi.org/10.1677/erc.1.00958.CrossRefPubMed

57.

Whitbread, A. K., Veveris-Lowe, T. L., Lawrence, M. G., Nicol, D. L., & Clements, J. A. (2006). The role of kallikrein-related peptidases in prostate cancer: potential involvement in an epithelial to mesenchymal transition. Biological Chemistry, 387(6), 707–714. https://doi.org/10.1515/BC.2006.089.CrossRefPubMed

58.

Cumming, A. P., Hopmans, S. N., Vukmirovic-Popovic, S., & Duivenvoorden, W. C. (2011). PSA affects prostate cancer cell invasion in vitro and induces an osteoblastic phenotype in bone in vivo. Prostate Cancer and Prostatic Diseases, 14(4), 286–294. https://doi.org/10.1038/pcan.2011.34.CrossRefPubMed

59.

Gkika, D., Flourakis, M., Lemonnier, L., & Prevarskaya, N. (2010). PSA reduces prostate cancer cell motility by stimulating TRPM8 activity and plasma membrane expression. Oncogene, 29(32), 4611–4616. https://doi.org/10.1038/onc.2010.210.CrossRefPubMed

60.

Downing, S., Bumak, C., Nixdorf, S., Ow, K., Russell, P., & Jackson, P. (2003). Elevated levels of prostate-specific antigen (PSA) in prostate cancer cells expressing mutant p53 is associated with tumor metastasis. Molecular Carcinogenesis, 38(3), 130–140. https://doi.org/10.1002/mc.10154.CrossRefPubMed

61.

Ishii, K., Otsuka, T., Iguchi, K., Usui, S., Yamamoto, H., Sugimura, Y., et al. (2004). Evidence that the prostate-specific antigen (PSA)/Zn2+ axis may play a role in human prostate cancer cell invasion. Cancer Letters, 207(1), 79–87. https://doi.org/10.1016/j.canlet.2003.09.029.CrossRefPubMed

62.

Rogers, O. C., Anthony, L., Rosen, D. M., Brennen, W. N., & Denmeade, S. R. (2018). PSA-selective activation of cytotoxic human serine proteases within the tumor microenvironment as a therapeutic strategy to target prostate cancer. Oncotarget, 9(32), 22436–22450. https://doi.org/10.18632/oncotarget.25091.CrossRefPubMedPubMedCentral

63.

Goya, M., Ishii, G., Miyamoto, S., Hasebe, T., Nagai, K., Yonou, H., et al. (2006). Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer. Prostate, 66(15), 1573–1584. https://doi.org/10.1002/pros.20375.CrossRefPubMed

64.

Sohara, Y., Shimada, H., & DeClerck, Y. A. (2005). Mechanisms of bone invasion and metastasis in human neuroblastoma. Cancer Letters, 228(1-2), 203–209. https://doi.org/10.1016/j.canlet.2005.01.059.CrossRefPubMed

65.

Nadiminty, N., Lou, W., Lee, S. O., Mehraein-Ghomi, F., Kirk, J. S., Conroy, J. M., et al. (2006). Prostate-specific antigen modulates genes involved in bone remodeling and induces osteoblast differentiation of human osteosarcoma cell line SaOS-2. Clinical Cancer Research, 12(5), 1420–1430. https://doi.org/10.1158/1078-0432.CCR-05-1849.CrossRefPubMed

66.

Cramer, S. D., Chen, Z., & Peehl, D. M. (1996). Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. The Journal of Urology, 156(2 Pt 1), 526–531. https://doi.org/10.1097/00005392-199608000-00076.CrossRefPubMed

67.

Yonou, H., Aoyagi, Y., Kanomata, N., Kamijo, T., Oda, T., Yokose, T., et al. (2001). Prostate-specific antigen induces osteoplastic changes by an autonomous mechanism. Biochemical and Biophysical Research Communications, 289(5), 1082–1087. https://doi.org/10.1006/bbrc.2001.6129.CrossRefPubMed

68.

D'Oronzo, S., Coleman, R., Brown, J., & Silvestris, F. (2019). Metastatic bone disease: pathogenesis and therapeutic options: up-date on bone metastasis management. Journal of Bone Oncology, 15, 004–004. https://doi.org/10.1016/j.jbo.2018.10.004.CrossRefPubMed

69.

Fidler, I. J. (2000). Angiogenesis and cancer metastasis. Cancer Journal, 6(Suppl 2), S134–S141.PubMed

70.

Heidtmann, H. H., Nettelbeck, D. M., Mingels, A., Jager, R., Welker, H. G., & Kontermann, R. E. (1999). Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen. British Journal of Cancer, 81(8), 1269–1273. https://doi.org/10.1038/sj.bjc.6692167.CrossRefPubMedPubMedCentral

71.

Chadha, K. C., Nair, B. B., Chakravarthi, S., Zhou, R., Godoy, A., Mohler, J. L., et al. (2011). Enzymatic activity of free-prostate-specific antigen (f-PSA) is not required for some of its physiological activities. Prostate, 71(15), 1680–1690. https://doi.org/10.1002/pros.21385.CrossRefPubMedPubMedCentral

72.

Jha, S. K., Rauniyar, K., Chronowska, E., Mattonet, K., Maina, E. W., Koistinen, H., et al. (2019). KLK3/PSA and cathepsin D activate VEGF-C and VEGF-D. Elife, 8. https://doi.org/10.7554/eLife.44478.

73.

Pampalakis, G., & Sotiropoulou, G. (2007). Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer. Biochimica et Biophysica Acta, 1776(1), 22–31. https://doi.org/10.1016/j.bbcan.2007.06.001.CrossRefPubMed

74.

Gorelik, L., & Flavell, R. A. (2001). Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nature Medicine, 7(10), 1118–1122. https://doi.org/10.1038/nm1001-1118.CrossRefPubMed

75.

Kiessling, A., Wehner, R., Fussel, S., Bachmann, M., Wirth, M. P., & Schmitz, M. (2012). Tumor-associated antigens for specific immunotherapy of prostate cancer. Cancers (Basel), 4(1), 193–217. https://doi.org/10.3390/cancers4010193.CrossRef

76.

Guo, S., Briza, P., Magdolen, V., Brandstetter, H., & Goettig, P. (2018). Activation and activity of glycosylated KLKs 3, 4 and 11. Biological Chemistry, 399(9), 1009–1022. https://doi.org/10.1515/hsz-2018-0148.CrossRefPubMed

77.

Yoon, H., Blaber, S. I., Evans, D. M., Trim, J., Juliano, M. A., Scarisbrick, I. A., et al. (2008). Activation profiles of human kallikrein-related peptidases by proteases of the thrombostasis axis. Protein Science, 17(11), 1998–2007. https://doi.org/10.1110/ps.036715.108.CrossRefPubMedPubMedCentral

78.

Yoon, H., Laxmikanthan, G., Lee, J., Blaber, S. I., Rodriguez, A., Kogot, J. M., et al. (2007). Activation profiles and regulatory cascades of the human kallikrein-related peptidases. The Journal of Biological Chemistry, 282(44), 31852–31864. https://doi.org/10.1074/jbc.M705190200.CrossRefPubMed

79.

Mikolajczyk, S. D., Millar, L. S., Kumar, A., & Saedi, M. S. (1999). Prostatic human kallikrein 2 inactivates and complexes with plasminogen activator inhibitor-1. International Journal of Cancer, 81(3), 438–442.CrossRefPubMed

80.

Charlesworth, M. C., Young, C. Y., Miller, V. M., & Tindall, D. J. (1999). Kininogenase activity of prostate-derived human glandular kallikrein (hK2) purified from seminal fluid. Journal of Andrology, 20(2), 220–229.PubMed

81.

Klokk, T. I., Kilander, A., Xi, Z., Waehre, H., Risberg, B., Danielsen, H. E., et al. (2007). Kallikrein 4 is a proliferative factor that is overexpressed in prostate cancer. Cancer Research, 67(11), 5221–5230. https://doi.org/10.1158/0008-5472.CAN-06-4728.CrossRefPubMed

82.

Avgeris, M., Mavridis, K., & Scorilas, A. (2010). Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies. Biological Chemistry, 391(5), 505–511. https://doi.org/10.1515/BC.2010.056.CrossRefPubMed

83.

Jin, Y., Qu, S., Tesikova, M., Wang, L., Kristian, A., Maelandsmo, G. M., et al. (2013). Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 110(28), E2572–E2581. https://doi.org/10.1073/pnas.1304318110.CrossRefPubMedPubMedCentral

84.

Avgeris, M., & Scorilas, A. (2016). Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies. Expert Opinion on Therapeutic Targets, 20(7), 801–818. https://doi.org/10.1517/14728222.2016.1147560.CrossRefPubMed

85.

Gao, J., Collard, R. L., Bui, L., Herington, A. C., Nicol, D. L., & Clements, J. A. (2007). Kallikrein 4 is a potential mediator of cellular interactions between cancer cells and osteoblasts in metastatic prostate cancer. Prostate, 67(4), 348–360. https://doi.org/10.1002/pros.20465.CrossRefPubMed

86.

Obiezu, C. V., Shan, S. J., Soosaipillai, A., Luo, L. Y., Grass, L., Sotiropoulou, G., et al. (2005). Human kallikrein 4: quantitative study in tissues and evidence for its secretion into biological fluids. Clinical Chemistry, 51(8), 1432–1442. https://doi.org/10.1373/clinchem.2005.049692.CrossRefPubMed

87.

Yousef, G. M., Scorilas, A., Chang, A., Rendl, L., Diamandis, M., Jung, K., et al. (2002). Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues. Prostate, 51(2), 126–132. https://doi.org/10.1002/pros.10067.CrossRefPubMed

88.

Kurlender, L., Yousef, G. M., Memari, N., Robb, J. D., Michael, I. P., Borgono, C., et al. (2004). Differential expression of a human kallikrein 5 (KLK5) splice variant in ovarian and prostate cancer. Tumour Biology, 25(3), 149–156. https://doi.org/10.1159/000079147.CrossRefPubMed

89.

Zhang, C. Y., Zhu, Y., Rui, W. B., Dai, J., & Shen, Z. J. (2015). Expression of kallikrein-related peptidase 7 is decreased in prostate cancer. Asian Journal of Andrology, 17(1), 106–110. https://doi.org/10.4103/1008-682X.137613.CrossRefPubMed

90.

Mo, L., Zhang, J., Shi, J., Xuan, Q., Yang, X., Qin, M., et al. (2010). Human kallikrein 7 induces epithelial-mesenchymal transition-like changes in prostate carcinoma cells: a role in prostate cancer invasion and progression. Anticancer Research, 30(9), 3413–3420.PubMed

91.

Hu, J., Lei, H., Fei, X., Liang, S., Xu, H., Qin, D., et al. (2015). NES1/KLK10 gene represses proliferation, enhances apoptosis and down-regulates glucose metabolism of PC3 prostate cancer cells. Scientific Reports, 5, 17426. https://doi.org/10.1038/srep17426.CrossRefPubMedPubMedCentral

92.

Olkhov-Mitsel, E., Van der Kwast, T., Kron, K. J., Ozcelik, H., Briollais, L., Massey, C., et al. (2012). Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer. Epigenetics, 7(9), 1037–1045. https://doi.org/10.4161/epi.21524.CrossRefPubMedPubMedCentral

93.

Stavropoulou, P., Gregorakis, A. K., Plebani, M., & Scorilas, A. (2005). Expression analysis and prognostic significance of human kallikrein 11 in prostate cancer. Clinica Chimica Acta, 357(2), 190–195. https://doi.org/10.1016/j.cccn.2005.03.026.CrossRef

94.

Lose, F., Batra, J., O'Mara, T., Fahey, P., Marquart, L., Eeles, R. A., et al. (2013). Common variation in Kallikrein genes KLK5, KLK6, KLK12, and KLK13 and risk of prostate cancer and tumor aggressiveness. Urologic Oncology, 31(5), 635–643. https://doi.org/10.1016/j.urolonc.2011.05.011.CrossRefPubMed

95.

Memari, N., Diamandis, E. P., Earle, T., Campbell, A., Van Dekken, H., & Van der Kwast, T. H. (2007). Human kallikrein-related peptidase 12: antibody generation and immunohistochemical localization in prostatic tissues. Prostate, 67(13), 1465–1474. https://doi.org/10.1002/pros.20596.CrossRefPubMed

96.

Rabien, A., Fritzsche, F., Jung, M., Diamandis, E. P., Loening, S. A., Dietel, M., et al. (2008). High expression of KLK14 in prostatic adenocarcinoma is associated with elevated risk of prostate-specific antigen relapse. Tumour Biology, 29(1), 1–8. https://doi.org/10.1159/000132565.CrossRefPubMed

97.

Mavridis, K., Avgeris, M., Koutalellis, G., Stravodimos, K., & Scorilas, A. (2010). Expression analysis and study of the KLK15 mRNA splice variants in prostate cancer and benign prostatic hyperplasia. Cancer Science, 101(3), 693–699. https://doi.org/10.1111/j.1349-7006.2009.01450.x.CrossRefPubMed

98.

Mavridis, K., Stravodimos, K., & Scorilas, A. (2013). Quantified KLK15 gene expression levels discriminate prostate cancer from benign tumors and constitute a novel independent predictor of disease progression. Prostate, 73(11), 1191–1201. https://doi.org/10.1002/pros.22667.CrossRefPubMed

99.

Batra, J., Lose, F., O'Mara, T., Marquart, L., Stephens, C., Alexander, K., et al. (2011). Association between Prostinogen (KLK15) genetic variants and prostate cancer risk and aggressiveness in Australia and a meta-analysis of GWAS data. PLoS One, 6(11), e26527. https://doi.org/10.1371/journal.pone.0026527.CrossRefPubMedPubMedCentral

100.

Schmitthenner, H. F., Dobson, D. E., Jones, K. G., Akporji, N., Soika, D. Q. M., Nastiuk, K. L., et al. (2019). Modular synthesis of DOTA-metal based PSMA targeted imaging agents for MRI and PET of prostate cancer. Chemistry. https://doi.org/10.1002/chem.201903390.CrossRefPubMed

101.

LeBeau, A. M., Banerjee, S. R., Pomper, M. G., Mease, R. C., & Denmeade, S. R. (2009). Optimization of peptide-based inhibitors of prostate-specific antigen (PSA) as targeted imaging agents for prostate cancer. Bioorganic & Medicinal Chemistry, 17(14), 4888–4893. https://doi.org/10.1016/j.bmc.2009.06.012.CrossRef

102.

Evans-Axelsson, S., Ulmert, D., Orbom, A., Peterson, P., Nilsson, O., Wennerberg, J., et al. (2012). Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone. Cancer Biotherapy & Radiopharmaceuticals, 27(4), 243–251. https://doi.org/10.1089/cbr.2011.1088.CrossRef

103.

Ulmert, D., Evans, M. J., Holland, J. P., Rice, S. L., Wongvipat, J., Pettersson, K., et al. (2012). Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen. Cancer Discovery, 2(4), 320–327. https://doi.org/10.1158/2159-8290.CD-11-0316.CrossRefPubMedPubMedCentral

104.

Timmermand, O. V., Ulmert, D., Evans-Axelsson, S., Pettersson, K., Bjartell, A., Lilja, H., et al. (2014). Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a (111)In-radiolabelled monoclonal antibody, 11B6. EJNMMI Research, 4(1), 51. https://doi.org/10.1186/s13550-014-0051-5.CrossRefPubMedPubMedCentral

105.

Koistinen, H., Wallen, E., Ylikangas, H., Meinander, K., Lahtela-Kakkonen, M., Narvanen, A., et al. (2016). Development of molecules stimulating the activity of KLK3 - an update. Biological Chemistry, 397(12), 1229–1235. https://doi.org/10.1515/hsz-2016-0189.CrossRefPubMed

106.

Costello, L. C., & Franklin, R. B. (2011). Zinc is decreased in prostate cancer: an established relationship of prostate cancer! Journal of Biological Inorganic Chemistry, 16(1), 3–8. https://doi.org/10.1007/s00775-010-0736-9.CrossRefPubMed

107.

Mavridis, K., Avgeris, M., & Scorilas, A. (2014). Targeting kallikrein-related peptidases in prostate cancer. Expert Opinion on Therapeutic Targets, 18(4), 365–383. https://doi.org/10.1517/14728222.2014.880693.CrossRefPubMed

108.

Koistinen, H., Wohlfahrt, G., Mattsson, J. M., Wu, P., Lahdenpera, J., & Stenman, U. H. (2008). Novel small molecule inhibitors for prostate-specific antigen. Prostate, 68(11), 1143–1151. https://doi.org/10.1002/pros.20773.CrossRefPubMed

109.

Santos, J. A., Kondo, M. Y., Freitas, R. F., dos Santos, M. H., Ramalho, T. C., Assis, D. M., et al. (2016). The natural flavone fukugetin as a mixed-type inhibitor for human tissue kallikreins. Bioorganic & Medicinal Chemistry Letters, 26(5), 1485–1489. https://doi.org/10.1016/j.bmcl.2016.01.039.CrossRef

110.

LeBeau, A. M., Singh, P., Isaacs, J. T., & Denmeade, S. R. (2008). Potent and selective peptidyl boronic acid inhibitors of the serine protease prostate-specific antigen. Chemistry & Biology, 15(7), 665–674. https://doi.org/10.1016/j.chembiol.2008.05.020.CrossRef

111.

Kostova, M. B., Rosen, D. M., Chen, Y., Mease, R. C., & Denmeade, S. R. (2013). Structural optimization, biological evaluation, and application of peptidomimetic prostate specific antigen inhibitors. Journal of Medicinal Chemistry, 56(11), 4224–4235. https://doi.org/10.1021/jm301718c.CrossRefPubMedPubMedCentral

112.

Adlington, R. M., Baldwin, J. E., Becker, G. W., Chen, B., Cheng, L., Cooper, S. L., et al. (2001). Design, synthesis, and proposed active site binding analysis of monocyclic 2-azetidinone inhibitors of prostate specific antigen. Journal of Medicinal Chemistry, 44(10), 1491–1508. https://doi.org/10.1021/jm000145g.CrossRefPubMed

113.

Huang, X., Knoell, C. T., Frey, G., Hazegh-Azam, M., Tashjian Jr., A. H., Hedstrom, L., et al. (2001). Modulation of recombinant human prostate-specific antigen: activation by Hofmeister salts and inhibition by azapeptides. Appendix: thermodynamic interpretation of the activation by concentrated salts. Biochemistry, 40(39), 11734–11741. https://doi.org/10.1021/bi010364j.CrossRefPubMed

114.

LeBeau, A. M., Kostova, M., Craik, C. S., & Denmeade, S. R. (2010). Prostate-specific antigen: an overlooked candidate for the targeted treatment and selective imaging of prostate cancer. Biological Chemistry, 391(4), 333–343. https://doi.org/10.1515/BC.2010.044.CrossRefPubMedPubMedCentral

115.

Goettig, P., Magdolen, V., & Brandstetter, H. (2010). Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs). Biochimie, 92(11), 1546–1567. https://doi.org/10.1016/j.biochi.2010.06.022.CrossRefPubMedPubMedCentral

116.

Law, R. H., Zhang, Q., McGowan, S., Buckle, A. M., Silverman, G. A., Wong, W., et al. (2006). An overview of the serpin superfamily. Genome Biology, 7(5), 216. https://doi.org/10.1186/gb-2006-7-5-216.CrossRefPubMedPubMedCentral

117.

Mating, F., Jeet, V., Srinivasan, S., Cristino, A. S., Panchadsaram, J., Clements, J. A., et al. (2019). MicroRNA-3162-5p-Mediated crosstalk between kallikrein family members including prostate-specific antigen in prostate cancer. Clinical Chemistry, 65(6), 771–780. https://doi.org/10.1373/clinchem.2018.295824.CrossRef

118.

Larne, O., Ostling, P., Haflidadottir, B. S., Hagman, Z., Aakula, A., Kohonen, P., et al. (2015). miR-183 in prostate cancer cells positively regulates synthesis and serum levels of prostate-specific antigen. European Urology, 68(4), 581–588. https://doi.org/10.1016/j.eururo.2014.12.025.CrossRefPubMed

119.

Sun, D., Lee, Y. S., Malhotra, A., Kim, H. K., Matecic, M., Evans, C., et al. (2011). miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation. Cancer Research, 71(4), 1313–1324. https://doi.org/10.1158/0008-5472.CAN-10-1031.CrossRefPubMedPubMedCentral

120.

Kostova, M. B., Brennen, W. N., Lopez, D., Anthony, L., Wang, H., Platz, E., et al. (2018). PSA-alpha-2-macroglobulin complex is enzymatically active in the serum of patients with advanced prostate cancer and can degrade circulating peptide hormones. Prostate, 78(11), 819–829. https://doi.org/10.1002/pros.23539.CrossRefPubMedPubMedCentral

121.

Thorek, D. L., Evans, M. J., Carlsson, S. V., Ulmert, D., & Lilja, H. (2013). Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging roles. Thrombosis and Haemostasis, 110(3), 484–492. https://doi.org/10.1160/TH13-04-0275.CrossRefPubMedPubMedCentral

122.

Ast, G. (2003). Drug-targeting strategies for prostate cancer. Current Pharmaceutical Design, 9(6), 455–466.CrossRefPubMed

123.

Denmeade, S. R., Jakobsen, C. M., Janssen, S., Khan, S. R., Garrett, E. S., Lilja, H., et al. (2003). Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. Journal of the National Cancer Institute, 95(13), 990–1000. https://doi.org/10.1093/jnci/95.13.990.CrossRefPubMed

124.

DeFeo-Jones, D., Garsky, V. M., Wong, B. K., Feng, D. M., Bolyar, T., Haskell, K., et al. (2000). A peptide-doxorubicin ‘prodrug’ activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo. Nature Medicine, 6(11), 1248–1252. https://doi.org/10.1038/81351.CrossRefPubMed

125.

Tai, W., Shukla, R. S., Qin, B., Li, B., & Cheng, K. (2011). Development of a peptide-drug conjugate for prostate cancer therapy. Molecular Pharmaceutics, 8(3), 901–912. https://doi.org/10.1021/mp200007b.CrossRefPubMedPubMedCentral

126.

Baiz, D., Pinder, T. A., Hassan, S., Karpova, Y., Salsbury, F., Welker, M. E., et al. (2012). Synthesis and characterization of a novel prostate cancer-targeted phosphatidylinositol-3-kinase inhibitor prodrug. Journal of Medicinal Chemistry, 55(18), 8038–8046. https://doi.org/10.1021/jm300881a.CrossRefPubMedPubMedCentral

127.

Li, B., Zhang, L. J., Zhang, Z. L., Long, M., Ren, J. H., Lin, F., et al. (2011). Synergistic tumor growth-inhibitory effect of the prostate-specific antigen-activated fusion peptide BSD352 for prostate cancer therapy. Anti-Cancer Drugs, 22(3), 213–222. https://doi.org/10.1097/CAD.0b013e3283401f4d.CrossRefPubMed

128.

Akinboye, E. S., Rosen, M. D., Bakare, O., & Denmeade, S. R. (2017). Anticancer activities of emetine prodrugs that are proteolytically activated by the prostate specific antigen (PSA) and evaluation of in vivo toxicity of emetine derivatives. Bioorganic & Medicinal Chemistry, 25(24), 6707–6717. https://doi.org/10.1016/j.bmc.2017.11.015.CrossRef

129.

Williams, S. A., Merchant, R. F., Garrett-Mayer, E., Isaacs, J. T., Buckley, J. T., & Denmeade, S. R. (2007). A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. Journal of the National Cancer Institute, 99(5), 376–385. https://doi.org/10.1093/jnci/djk065.CrossRefPubMed

130.

Sinha, A. A., Quast, B. J., Reddy, P. K., Elson, M. K., & Wilson, M. J. (1999). Intravenous injection of an immunoconjugate (anti-PSA-IgG conjugated to 5-fluoro-2′-deoxyuridine) selectively inhibits cell proliferation and induces cell death in human prostate cancer cell tumors grown in nude mice. Anticancer Research, 19(2A), 893–902.PubMed

131.

Madan, R. A., Arlen, P. M., Mohebtash, M., Hodge, J. W., & Gulley, J. L. (2009). Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opinion on Investigational Drugs, 18(7), 1001–1011. https://doi.org/10.1517/13543780902997928.CrossRefPubMedPubMedCentral

132.

Sonpavde, G., Agarwal, N., Choueiri, T. K., & Kantoff, P. W. (2011). Recent advances in immunotherapy for the treatment of prostate cancer. Expert Opinion on Biological Therapy, 11(8), 997–1009. https://doi.org/10.1517/14712598.2011.575357.CrossRefPubMed

133.

Karan, D., Dubey, S., Van Veldhuizen, P., Holzbeierlein, J. M., Tawfik, O., & Thrasher, J. B. (2011). Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice. Immunotherapy, 3(6), 735–746. https://doi.org/10.2217/imt.11.59.CrossRefPubMed

134.

Miller, A. M., Ozenci, V., Kiessling, R., & Pisa, P. (2005). Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer. Journal of Immunotherapy, 28(4), 389–395.CrossRefPubMed

135.

Katzenwadel, A., Schleer, H., Gierschner, D., Wetterauer, U., & Elsasser-Beile, U. (2000). Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer. Anticancer Research, 20(3A), 1551–1555.PubMed

136.

Daniels-Wells, T. R., Helguera, G., Leuchter, R. K., Quintero, R., Kozman, M., Rodriguez, J. A., et al. (2013). A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy. BMC Cancer, 13, 195. https://doi.org/10.1186/1471-2407-13-195.CrossRefPubMedPubMedCentral

137.

DiPaola, R. S., Rinehart, J., Nemunaitis, J., Ebbinghaus, S., Rubin, E., Capanna, T., et al. (2002). Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer. Journal of Clinical Oncology, 20(7), 1874–1879. https://doi.org/10.1200/JCO.2002.07.001.CrossRefPubMed

138.

Elsadek, B., Graeser, R., Warnecke, A., Unger, C., Saleem, T., El-Melegy, N., et al. (2010). Optimization of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen. ACS Medicinal Chemistry Letters, 1(5), 234–238. https://doi.org/10.1021/ml100060m.CrossRefPubMedPubMedCentral

139.

Mhaka, A., Denmeade, S. R., Yao, W., Isaacs, J. T., & Khan, S. R. (2002). A 5-fluorodeoxyuridine prodrug as targeted therapy for prostate cancer. Bioorganic & Medicinal Chemistry Letters, 12(17), 2459–2461.CrossRef

140.

DeFeo-Jones, D., Brady, S. F., Feng, D. M., Wong, B. K., Bolyar, T., Haskell, K., et al. (2002). A prostate-specific antigen (PSA)-activated vinblastine prodrug selectively kills PSA-secreting cells in vivo. Molecular Cancer Therapeutics, 1(7), 451–459.PubMed

141.

Elsadek, B., Graeser, R., Esser, N., Schafer-Obodozie, C., Abu Ajaj, K., Unger, C., et al. (2010). Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen: an in vitro and in vivo evaluation study. European Journal of Cancer, 46(18), 3434–3444. https://doi.org/10.1016/j.ejca.2010.08.018.CrossRefPubMed

142.

Chandran, S. S., Nan, A., Rosen, D. M., Ghandehari, H., & Denmeade, S. R. (2007). A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer. Molecular Cancer Therapeutics, 6(11), 2928–2937. https://doi.org/10.1158/1535-7163.MCT-07-0392.CrossRefPubMed

143.

Latham, J. P., Searle, P. F., Mautner, V., & James, N. D. (2000). Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Research, 60(2), 334–341.PubMed

144.

Figueiredo, M. L., Sato, M., Johnson, M., & Wu, L. (2006). Specific targeting of gene therapy to prostate cancer using a two-step transcriptional amplification system. Future Oncology, 2(3), 391–406. https://doi.org/10.2217/14796694.2.3.391.CrossRefPubMed

145.

Yu, D., Chen, D., Chiu, C., Razmazma, B., Chow, Y. H., & Pang, S. (2001). Prostate-specific targeting using PSA promoter-based lentiviral vectors. Cancer Gene Therapy, 8(9), 628–635. https://doi.org/10.1038/sj.cgt.7700344.CrossRefPubMed

146.

Gerritsen, W. R. (2012). The evolving role of immunotherapy in prostate cancer. Annals of Oncology, 23(Suppl 8), viii22–viii27. https://doi.org/10.1093/annonc/mds259.CrossRefPubMed

147.

Gulley, J. L., Borre, M., Vogelzang, N. J., Ng, S., Agarwal, N., Parker, C. C., et al. (2019). Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 37(13), 1051–1061. https://doi.org/10.1200/JCO.18.02031.CrossRefPubMedPubMedCentral

148.

Joniau, S., Abrahamsson, P. A., Bellmunt, J., Figdor, C., Hamdy, F., Verhagen, P., et al. (2012). Current vaccination strategies for prostate cancer. European Urology, 61(2), 290–306. https://doi.org/10.1016/j.eururo.2011.09.020.CrossRefPubMed

149.

Geary, S. M., & Salem, A. K. (2013). Prostate cancer vaccines: update on clinical development. Oncoimmunology, 2(5), e24523. https://doi.org/10.4161/onci.24523.CrossRefPubMedPubMedCentral

Springer Medizin

Beyond the biomarker role: prostate-specific antigen (PSA) in the prostate cancer microenvironment

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

Cell surface–anchored serine proteases in cancer progression and metastasis

Current management of succinate dehydrogenase–deficient gastrointestinal stromal tumors

Spatio-temporal modeling and live-cell imaging of proteolysis in the 4D microenvironment of breast cancer

The role of proteases in epithelial-to-mesenchymal cell transitions in cancer